NTL Healthcare Secures Vietnam Ministry of Health Budget Approval. Nationwide ‘CerviCARE® AI’ Screening Project for 50,000 Women Moves into Full-Scale Implementation
- Vietnam’s National Broadcaster VTV Highlights the Initiative, While Partnership with the Ho Chi Minh City Labor Federation Launches Large-Scale Cervical Cancer Screening for 50,000 Female Workers. - Establishment of a new standard for public screening through digital healthcare, accelerating towards 2027 IPO and global expansion. NTL HEALTHCARE, a Fem-Tech digital healthcare company specializing in women’s health (CEO: Taehee Kim), announced on the 21st that it has officially launched a cervical cancer screening project using CerviCARE® AI targeting 50,000 female workers in Vietnam, in collaboration with the Ho Chi Minh City Labor Federation and local healthcare institutions, supported by the official budge t of the Vietnam Ministry of Health (MoH) This project is being recognized as a pioneering case in which the Vietnamese government directly allocated funding to introduce innovative digital healthcare technology into the national public screening system. Since the official launch on the 9th, more than 12,000 local female workers have already completed screening, and the initiative is now being actively expanded nationwide as part of a government-led public health campaign during Vietnam’s “Workers’ Month.” In particular, the project drew significant public attention after being featured in a detailed report on the main news program of Vietnam’s largest state-owned broadcaster, VTV (Vietnam Television). VTV highlighted that ‘CerviCARE® AI’ became the first AI-powered medical device approved by the Vietnamese Ministry of Health in the field of cervical cancer diagnosis, while spotlighting how the technology is emerging as a new standard within the country’s national healthcare system. At screening sites including Hung Vuong Hospital, healthcare institutions have adopted an innovative protocol in which CerviCARE® AI is used as a primary screening tool, replacing conventional cytology at the initial screening stage. NTL Healthcare’s on-device AI technology is being recognized for delivering highly accurate results within five seconds, even in environments with limited internet connectivity. The technology is also praised for overcoming the limitations of conventional screening methods, which often require several weeks for results, while significantly improving cost efficiency. The technology demonstrated 98% sensitivity for high-grade lesions (Scientific Reports, 2024), supporting its reliability in large-scale screening settings. Building on this national-scale reference project involving 50,000 participants, NTL Healthcare plans to accelerate expansion not only across Southeast Asia but also into Central Asia, Africa, and Latin America. Taehee Kim, CEO of NTL Healthcare , stated “This project, funded by the Vietnam Ministry of Health, will serve as one of the strongest showcases demonstrating the innovation and real-world applicability of CerviCARE® AI on the global stage. Based on our growing international achievements and commercial momentum, our preparations for a KOSDAQ IPO in 2027 has been further strengthened.” ”We are actively seeking global pharmaceutical companies, medical device distribution partners, and strategic investors who can create synergies with our differentiated AI diagnostic platform and join us in expanding across the world. Beyond supplying technology, we look forward to collaborating with partners who share our vision of transforming the global women’s health ecosystem.” Following recognition through the CES 2026 Innovation Award and approval of its on-device Class III medical device, NTL Healthcare aims to strengthen partnerships with international organizations including UNICEF and the WHO in advancing global cervical cancer elimination efforts. About NTL Healthcare NTL Healthcare is a global Fem-Tech digital healthcare company that has specialized in developing diagnostic systems and platforms for women’s health for over 30 years. The company pioneered the Korean market by introducing the world’s first image-based cervical cancer diagnostic method and has developed CerviCARE® AI, an innovative AI-assisted cervical cancer screening system built upon decades of accumulated clinical big data. Leveraging its differentiated technology, NTL Healthcare received the CES 2026 Innovation Award and obtained approval for an on-device AI-based Class III medical device, setting a new standard for next-generation diagnostic solutions. The company is currently leading national screening initiatives in countries including Vietnam and aims to achieve a KOSDAQ IPO by the end of 2027, while driving digital healthcare innovation to improve women’s health worldwide. ReferenceOuh et al. (2024). Development and validation of artificial intelligence-based analysis software to support screening system of cervical intraepithelial neoplasia. Scientific Reports. 정현식 기자implementation healthcare digital healthcare local healthcare vietnam ministry
2026.05.25. 18:37
